UK markets closed

Advanced Oncotherapy PLC (AVO.L)

LSE - LSE Delayed price. Currency in GBp
Add to watchlist
43.00-0.50 (-1.15%)
At close: 4:35PM GMT
Full screen
Previous close43.50
Open42.61
Bid40.00 x 0
Ask43.00 x 0
Day's range40.35 - 43.00
52-week range20.00 - 50.00
Volume88,571
Avg. volume261,814
Market cap143.508M
Beta (5Y monthly)1.06
PE ratio (TTM)N/A
EPS (TTM)-9.80
Earnings date29 Sep 2020
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est155.00
  • How Much Of Advanced Oncotherapy plc (LON:AVO) Do Insiders Own?
    Simply Wall St.

    How Much Of Advanced Oncotherapy plc (LON:AVO) Do Insiders Own?

    If you want to know who really controls Advanced Oncotherapy plc (LON:AVO), then you'll have to look at the makeup of...

  • EQS Group

    Hardman & Co Research: Advanced Oncotherapy (AVO): Confidence in LIGHT gaining momentum

    Hardman & Co Research 17-Feb-2020 / 11:45 GMT/BST Hardman & Co Research: Confidence in LIGHT gaining momentumAVO's goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked through important technical milestones. AVO is working on the verification and validation phase, prior to CE marking and LIGHT being used on the first patients. The company has made two important commercial announcements regarding the installation of LIGHT systems, which highlights the increasing confidence that is building in AVO's ability to deliver LIGHT in the near future.Please click on the link below for the full report:https://www.hardmanandco.com/research/corporate-research/confidence-in-light-gaining-momentum/If you are interested in meeting the company, you can register your interest by clicking on the above linkTo contact us:Hardman & Co 35 New Broad Street London EC2M 1NHwww.hardmanandco.comFollow us on Twitter @HardmanandCoContact:Martin Hall +44 20 7194 7632 mh@hardmanandco.com Hardman & Co Research can still be accessed for free after MiFID II. Please click here to read the statement.About Hardman & Co: For the past 25 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case. Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer. * * *Dissemination of a CORPORATE NEWS, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement. * * * End of Announcement - EQS News Service